EMA Authorised: Twynsta (telmisartan;amlodipine) — Boehringer Ingelheim International GmbH

View source ↗

Summary

The EMA authorised Twynsta, a fixed-dose combination of telmisartan and amlodipine, for the treatment of hypertension. The decision was made for Boehringer Inge…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Amlodipine (amlodipine)
• Telmisartan (Telmisartan)

Snippet

Status: Authorised. Therapeutic area: Hypertension. MAH: Boehringer Ingelheim International GmbH. Decision date: 23/04/2026